Skip to main content
Atrás
Watch Compare

Prelude Therapeutics Inc

Calidad de datos: 100%
PRLD
Nasdaq Manufacturing Chemicals
$4.37
▲ $0.15 (3.55%)
Cap. Mercado: 274.72 M
Precio
$4.37
Cap. Mercado
274.72 M
Rango del Día
$3.83 — $4.45
Rango de 52 Semanas
$0.63 — $4.82
Volumen
158,172
Apertura $4.20
Promedio 50D / 200D
$2.76
58.28% above
Promedio 50D / 200D
$1.75
150.13% above

Quick Summary

Puntos Clave

Negative free cash flow of -56.37 M
Capital efficient — spends only 0.55% of revenue on capex

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)73.43%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-148.09%
Below sector avg (-53.47%)
ROIC-96.86%
Net Margin-819.59%
Op. Margin-861.33%

Seguridad

Debt / Equity
N/A
Current Ratio3.21
Interest CoverageN/A

Valoración

PE (TTM)
-2.76
Below sector avg (-1.47)
P/B Ratio4.69
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -2.8 -1.5
P/B 4.7 1.6
ROE % -148.1 -53.5
Net Margin % -819.6 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

BRSIX BRSIX
0.07% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 73.43% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 12.14 M Net Income (TTM) -99.50 M
ROE -148.09% ROA -94.91%
Gross Margin N/A Operating Margin -861.33%
Net Margin -819.59% Free Cash Flow (TTM) -56.37 M
ROIC -96.86% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3.21
Interest Coverage N/A Asset Turnover 0.12
Working Capital 40.14 M Tangible Book Value 58.53 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.76 Forward P/E N/A
P/B Ratio 4.69 P/S Ratio 22.63
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -20.52%
Market Cap 274.72 M Enterprise Value 227.19 M
Per Share
EPS (Diluted TTM) -1.29 Revenue / Share 0.19
FCF / Share -0.90 OCF / Share -0.90
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.55% FCF Conversion 56.65%
SBC-Adj. FCF -71.99 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 12.14 M 7.00 M — — —
Net Income -99.50 M -127.17 M -121.83 M -115.44 M -111.69 M
EPS (Diluted) -1.29 -1.68 -2.02 -2.44 —
Gross Profit — — — — —
Operating Income -104.57 M -139.71 M -132.28 M -123.54 M -113.74 M
EBITDA — — — — —
R&D Expenses 94.30 M 118.00 M 103.39 M 92.89 M 86.78 M
SG&A Expenses — — — — —
D&A 1.71 M 1.77 M 1.17 M 1.32 M 915,000.0
Interest Expense — — — — —
Income Tax 0.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 141.32 M 175.52 M 277.67 M 220.50 M 305.10 M
Total Liabilities 72.68 M 44.06 M 40.58 M 25.06 M 19.20 M
Shareholders' Equity 68.64 M 131.46 M 237.09 M 195.44 M 285.90 M
Total Debt — — — — —
Cash & Equivalents 35.26 M 12.47 M 25.29 M 30.61 M 31.83 M
Current Assets 105.69 M 135.90 M 235.59 M 204.38 M 295.12 M
Current Liabilities 52.99 M 25.64 M 21.83 M 21.70 M 19.20 M